<div id="readability-page-1"><p>American Trust raised its stake in  Eli Lilly and Company (NYSE:LLY - Free Report) by 147.1% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 6,122 shares of the company's stock after acquiring an additional 3,644 shares during the period. American Trust's holdings in Eli Lilly and Company were worth $4,772,000 as of its most recent SEC filing.</p><div><p><span></span><span>Get <strong>Eli Lilly and Company</strong> alerts:</span></p></div><ul><li>Golden Cross Alert: 3 Stocks With Major Upside Potential</li></ul><p>Other large investors have also recently modified their holdings of the company. Evolution Wealth Management Inc. purchased a new stake in  Eli Lilly and Company during the 2nd quarter valued at about $29,000.  Lavaca Capital LLC lifted its stake in shares of  Eli Lilly and Company by 8.4% in the second quarter. Lavaca Capital LLC now owns 1,303 shares of the company's stock worth $1,016,000 after buying an additional 101 shares in the last quarter.  China Universal Asset Management Co. Ltd. lifted its stake in shares of  Eli Lilly and Company by 9.6% in the second quarter. China Universal Asset Management Co. Ltd. now owns 7,750 shares of the company's stock worth $6,041,000 after buying an additional 678 shares in the last quarter.  Orion Porfolio Solutions LLC grew its holdings in shares of  Eli Lilly and Company by 7.2% during the second quarter. Orion Porfolio Solutions LLC now owns 50,823 shares of the company's stock valued at $39,618,000 after buying an additional 3,399 shares during the last quarter.  Finally, Munro Partners bought a new stake in shares of  Eli Lilly and Company during the second quarter valued at approximately $98,872,000. Hedge funds and other institutional investors own  82.53% of the company's stock. </p><h2>Eli Lilly and Company Trading Up 1.8%</h2><p>Shares of NYSE:LLY opened at $1,027.68 on Monday. The stock's 50-day simple moving average is $939.47 and its two-hundred day simple moving average is $820.35. The stock has a market capitalization of $971.55 billion, a price-to-earnings ratio of 50.28, a PEG ratio of 1.14 and a beta of 0.37. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,111.99. The company has a debt-to-equity ratio of 1.71, a quick ratio of 1.24 and a current ratio of 1.55. </p><ul><li>The Top 3 Investment Themes That Will Dominate 2026</li></ul><p>Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The company had revenue of $17.60 billion for the quarter, compared to the consensus estimate of $16.09 billion. During the same quarter last year, the firm posted $1.18 earnings per share. The firm's revenue was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS.  Analysts expect that  Eli Lilly and Company will post 23.48 EPS for the current year. </p><h2>Eli Lilly and Company Increases Dividend</h2><p>The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be issued a $1.73 dividend. The ex-dividend date of this dividend is Friday, February 13th. This represents a $6.92 dividend on an annualized basis and a yield of 0.7%. This is an increase from Eli Lilly and Company's previous quarterly dividend of $1.50. Eli Lilly and Company's payout ratio is 29.35%. </p><h2>Analyst Ratings Changes</h2><ul><li>5 Healthcare Names to Watch as Sector Rotation Is in Full Swing</li></ul><p>LLY has been the topic of several analyst reports. The Goldman Sachs Group upped their price objective on Eli Lilly and Company from $951.00 to $1,145.00 and gave the company a &#34;buy&#34; rating in a research report on Monday, December 8th. Leerink Partners raised Eli Lilly and Company from a &#34;market perform&#34; rating to an &#34;outperform&#34; rating and upped their price target for the company from $886.00 to $1,104.00 in a report on Monday, November 10th. JPMorgan Chase &amp; Co. increased their price objective on Eli Lilly and Company from $1,050.00 to $1,150.00 and gave the company an &#34;overweight&#34; rating in a research report on Tuesday, November 18th. Daiwa America lowered Eli Lilly and Company from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research report on Sunday, August 17th. Finally, National Bankshares  set a $1,286.00 target price on shares of Eli Lilly and Company in a research note on Monday, December 1st. Three research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have issued  a Hold rating to the company. According to MarketBeat, Eli Lilly and Company presently has an average rating of &#34;Moderate Buy&#34; and an average target price of $1,121.90.</p><p><b>Get Our Latest Report on Eli Lilly and Company</b></p><h2>About Eli Lilly and Company</h2> (Free Report)<p>Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Eli Lilly and Company</li><li>ETF Screener: Uses and Step-by-Step Guide </li><li>Dave &amp; Buster’s Reversal Is in PLAY After Double-Bottom Breakout</li><li>How to Find Undervalued Stocks</li><li>3 Finance Stocks to Buy on Rising 10-Year Treasury Rates</li><li>How Technical Indicators Can Help You Find Oversold Stocks </li><li>Disney's $1 Billion Deal Brings Its Magic to OpenAI</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Eli Lilly and Company Right Now?</h2><p>Before you consider Eli Lilly and Company, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.</p><p>While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>American Trust increased its stake in Eli Lilly and Company by 147.1% in Q2, now holding 6,122 shares valued at $4.77 million. Eli Lilly's stock opened at $1,027.68, with a market cap of $971.55 billion. The company reported Q3 earnings of $7.02 per share, surpassing estimates, and announced a dividend increase. Analysts have raised price targets, with Goldman Sachs setting a target of $1,145.00.</p>

American Trust Buys 3,644 Shares of Eli Lilly and Company $LLY